Anti-NFkB p100/NFKB2 antibody (ab131539)
Key features and details
- Rabbit polyclonal to NFkB p100/NFKB2
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-NFkB p100/NFKB2 antibody
See all NFkB p100/NFKB2 primary antibodies -
Description
Rabbit polyclonal to NFkB p100/NFKB2 -
Host species
Rabbit -
Specificity
The antibody detects endogenous level of total NFkB-p100 protein. -
Tested Applications & Species
Application Species ICC/IF HumanIHC-P HumanWB Human -
Immunogen
Synthetic peptide corresponding to Human NFkB p100/NFKB2 aa 870-874 conjugated to keyhole limpet haemocyanin.
Sequence:S-Q-S-V-E
Database link: Q00653 -
Positive control
- HeLa cells; HT29 cell extract; Human lung carcinoma tissue
-
General notes
This antibody detects sites on p100 only. Sometimes there is a 52kDa band on WB; this is not p52. There is a cleavage site on the NFKB2 (Swiss-Prot No.: Q00653). The cleavage site is between 454 and 455 (cleavage when cotranslationally processed). The antibody can interact with the C-half sometimes. The MW. of C-half is near 52Kd.
This product was previously labelled as NFkB p100
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.88% Sodium chloride
PBS without Mg2+ and Ca2+ -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab131539 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Application | Species |
---|---|
ICC/IF |
Human
|
IHC-P |
Human
|
WB |
Human
|
All applications |
Rat
|
Application | Abreviews | Notes |
---|---|---|
WB |
1/500 - 1/1000. Predicted molecular weight: 97 kDa.
|
|
IHC-P |
1/50 - 1/100.
|
|
ICC/IF |
1/100 - 1/200.
|
Notes |
---|
WB
1/500 - 1/1000. Predicted molecular weight: 97 kDa. |
IHC-P
1/50 - 1/100. |
ICC/IF
1/100 - 1/200. |
Target
-
Relevance
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. -
Cellular localization
Cytoplasmic and Nuclear -
Database links
- Entrez Gene: 4791 Human
- Entrez Gene: 309452 Rat
- Omim: 164012 Human
- SwissProt: Q00653 Human
- Unigene: 73090 Human
- Unigene: 204814 Rat
-
Alternative names
- CVID10 antibody
- DNA binding factor KBF2 antibody
- H2TF1 antibody
see all
Images
-
All lanes : Anti-NFkB p100/NFKB2 antibody (ab131539) at 1/500 dilution
Lane 1 : HT29 cell extract with blocking peptide
Lane 2 : HT29 cell extract
Predicted band size: 97 kDa -
Immunofluorescence analysis of methanol-fixed HeLa cells labelling NFkB p100/NFKB2 with ab131539 at 1/100 dilution.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NFkB p100/NFKB2 antibody (ab131539)
Immunohistochemical analysis of paraffin-embedded Human lung carcinoma tissue labelling NFkB p100/NFKB2 with ab131539 at 1/50 dilution. Right panel was preincubated with blocking peptide.
Protocols
Datasheets and documents
References (3)
ab131539 has been referenced in 3 publications.
- Chen Z et al. Two-layer regulation of TRAF6 mediated by both TLR4/NF-kB signaling and miR-589-5p increases proinflammatory cytokines in the pathology of severe acute pancreatitis. Am J Transl Res 12:2379-2395 (2020). PubMed: 32655778
- McDonald MK et al. Regulation of proinflammatory genes by the circulating microRNA hsa-miR-939. Sci Rep 6:30976 (2016). ICC . PubMed: 27498764
- Xu J et al. Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NF?B2 (p100). Oncotarget 7:34112-30 (2016). PubMed: 27095572